Ryan Bijan Khodadadi

Ryan Bijan Khodadadi

Auto-generated profile, based on publicly available information

Ryan Bijan Khodadadi

Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAparna Shinde
Aparna Shinde
SHShana D. Hardy
Shana D. Hardy
DKDongwook Kim
Dongwook Kim
SASaeed Salehin Akhand
Saeed Salehin Akhand
MJMohit Kumar Jolly
Mohit Kumar Jolly
MWMichael Wendt
Michael Wendt
The ability of breast cancer cells to transiently transition between epithelial and mesenchymal states contributes to their metastatic potential. Therefore, driving tumor cells into a stable mesenchymal state, as opposed to complete tumor cell eradication, presents an opportunity to pharmacologically limit disease progression by promoting an asymptomatic state of dormancy. Here, we compare a reversible model of epithelial–mesenchymal transition (EMT) induced by TGFβ to a stable mesenchymal phenotype induced by chronic exposure to the ErbB kinase inhibitor lapatinib. Only cells capable of returning to an epithelial phenotype resulted in skeletal metastasis. Gene expression analyses of the two mesenchymal states indicated similar transition expression profiles. A potently downregulated gene in both datasets was spleen tyrosine kinase (SYK). In contrast to this similar diminution in mRNA, kinome analyses using a peptide array and DNA-conjugated peptide substrates showed a robust increase in SYK activity upon TGFβ-induced EMT only. SYK was present in cytoplasmic RNA processing depots known as P-bodies formed during the onset of EMT, and SYK activity was required for autophagy-mediated clearance of P-bodies during mesenchymal–epithelial transition (MET). Genetic knockout of autophagy-related 7 (ATG7) or pharmacologic inhibition of SYK activity with fostamatinib, a clinically approved inhibitor of SYK, prevented P-body clearance and MET, inhibiting metastatic tumor outgrowth. Overall, this study suggests assessment of SYK activity as a biomarker for metastatic disease and the use of fostamatinib as a means to stabilize the latency of disseminated tumor cells. Significance: These findings present inhibition of spleen tyrosine kinase as a therapeutic option to limit breast cancer metastasis by promoting systemic tumor dormancy. Graphical http://cancerres.aacrjournals.org/content/canres/79/8/1831/F1.large.jpg. See related commentary by Farrington and Narla, p. 1756 Graphical Abstract

1 August 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZYZachary A Yetmar
Zachary A Yetmar
RKRyan B Khodadadi
Ryan B Khodadadi
SCSupavit Chesdachai
Supavit Chesdachai
JMJack W McHugh
Jack W McHugh
DCDouglas W Challener
Douglas W Challener
EBElena Beam
Elena Beam
Nocardia primarily infects patients who are immunocompromised or those with chronic lung disease. Although disseminated infection is widely recognized as an important prognostic factor, studies have been mixed on its impact on outcomes of nocardiosis. We performed a retrospective cohort study of adults with culture-confirmed nocardiosis. Advanced infection was defined as disseminated infection, cavitary pulmonary infection, or pleural infection. The primary outcome was 1-year mortality, as analyzed by multivariable Cox regression. Of 511 patients with culture growth of Nocardia, 374 (73.2%) who had clinical infection were included. The most common infection sites were pulmonary (82.6%), skin (17.9%), and central nervous system (14.2%). In total, 117 (31.3%) patients had advanced infection, including 74 (19.8%) with disseminated infection, 50 (13.4%) with cavitary infection, and 18 (4.8%) with pleural infection. Fifty-nine (15.8%) patients died within 1 year. In multivariable models, disseminated infection was not associated with mortality (hazard ratio, 1.16; 95% CI, .62–2.16; P = .650) while advanced infection was (hazard ratio, 2.48; 95% CI, 1.37–4.49; P = .003). N. farcinica, higher Charlson Comorbidity Index, and culture-confirmed pleural infection were also associated with mortality. Immunocompromised status and combination therapy were not associated with mortality. Advanced infection, rather than dissemination alone, predicted worse 1-year mortality after nocardiosis. N. farcinica was associated with mortality, even after adjusting for extent of infection. While patients who were immunocompromised had high rates of disseminated and advanced infection, immunocompromised status did not predict mortality after adjustment. Future studies should account for high-risk characteristics and specific infection sites rather than dissemination alone.

1 March 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZYZachary A Yetmar
Zachary A Yetmar
RKRyan B Khodadadi
Ryan B Khodadadi
SCSupavit Chesdachai
Supavit Chesdachai
JMJack McHugh
Jack McHugh
DCDouglas W. William Challener
Douglas W. William Challener
EBElena Beam
Elena Beam
Nocardia tends to cause infection in immunocompromised patients or those with chronic pulmonary disease. Nocardia is known to recur, prompting the practice of secondary prophylaxis in patients perceived at high risk. However, few data exist regarding the epidemiology of recurrent nocardiosis or the effectiveness of secondary prophylaxis. We performed a multicenter, retrospective cohort study of adults diagnosed with nocardiosis from November 2011 to April 2022, including patients who completed primary treatment and had at least 30 days of posttreatment follow-up. Propensity score matching was used to analyze the effect of secondary prophylaxis on Nocardia recurrence. Fifteen of 303 (5.0%) patients developed recurrent nocardiosis after primary treatment. Most recurrences were diagnosed either within 60 days (N = 6/15, 40.0%) or between 2 to 3 years (N = 4/15, 26.7%). Patients with primary disseminated infection tended to recur within 1 year, whereas later recurrences were often nondisseminated pulmonary infection. Seventy-eight (25.7%) patients were prescribed secondary prophylaxis, mostly trimethoprim-sulfamethoxazole (N = 67/78). After propensity-matching, secondary prophylaxis was not associated with reduced risk of recurrence (hazard ratio, 0.96; 95% confidence interval, .24–3.83), including in multiple subgroups. Eight (53.3%) patients with recurrent nocardiosis required hospitalization and no patients died from recurrent infection. Recurrent nocardiosis tends to occur either within months because of the same Nocardia species or after several years with a new species. Although we did not find evidence for the effectiveness of secondary prophylaxis, the confidence intervals were wide. However, outcomes of recurrent nocardiosis are generally favorable and may not justify long-term antibiotic prophylaxis for this indication alone.

12 December 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
NRNischal Ranganath
Nischal Ranganath
RKRyan B Khodadadi
Ryan B Khodadadi
OSOmar M Abu Saleh
Omar M Abu Saleh
The diagnosis of Q fever can be challenging and a high index of suspicion is necessary. Within this case series, we highlight the utility of the microbial cell-free DNA next-generation sequencing or Karius Test in the timely diagnosis and management of acute Q fever.

23 August 2023 in JAAD International
Verified
Journal Article
Open access
RKRyan B. Khodadadi
Ryan B. Khodadadi
ZYZachary A. Yetmar
Zachary A. Yetmar
CMCarmen M. Montagnon
Carmen M. Montagnon
EJEmma F. Johnson
Emma F. Johnson
OSOmar M. Abu Saleh
Omar M. Abu Saleh
Majocchi's granuloma (MG) is an uncommon deep fungal folliculitis predominantly caused by dermatophytes. Given the rarity of this condition, available data regarding predisposing comorbidities/risk factors, clinical characteristics, offending microbiologic pathogens, diagnostics, pathologic findings, and treatment approaches has been inferred from historical cases. To review our institutional experience with MG. We retrospectively analyzed a multicenter cohort of adult patients diagnosed with MG between 1992 and 2022. We analyzed 147 patients with MG, 105 of which were male with a median age of 55.6 years. Immunosuppressant and topical corticosteroid use were common prior to development of MG. Dermatologic lesions and their sites of involvement did not differ based on the immune status of patients. Trichophyton rubrum was the most common causative pathogen of MG, in addition to other dermatophytes. Treatment duration for all prescribed agents was median 31.5 days with oral terbinafine being the most frequently utilized agent. Clinical resolution was achieved in 96.6% of cases. Retrospective, nonrandomized study. Although rare and clinically variable in presentation, diagnosis of MG often requires histopathologic confirmation to subsequently direct prolonged treatment with systemic antifungal therapy for mycological cure.

14 April 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZYZachary A Yetmar
Zachary A Yetmar
RKRyan B Khodadadi
Ryan B Khodadadi
MSMaria Teresa Seville
Maria Teresa Seville
LBLisa Brumble
Lisa Brumble
JOJohn C O’hOro
John C O’hOro
RRRaymund R. Razonable
Raymund R. Razonable
Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.